Abbott Gets CDSCO Approval For Marketing Of Estradiol Dydrogesterone FDC

Abbott Gets CDSCO Approval For Marketing Of Estradiol Dydrogesterone FDC

Abbott, the global healthcare company, has received approval from the Subject Expert Committee (SEC) at Central Drugs Standard Control Organisation (CDSCO) for importing and marketing of the fixed dose combination of dydrogesterone+estradiol (2.5 mg + 0.5mg) tablets.The firm presented the trial data with respect to Asian population as per the recommendation of earlier SEC held on September 23, 2020.After detailed deliberation, the committee considered phase III CT waiver and recommended for grant of permission for import and market of the subject FDC subject to the condition that the firm should submit the phase IV clinical trial protocol within 3 months of approval of the FDC.Estradiol/dydrogesterone (E2/DYD), sold under the brand name Femoston among others, is a combination of estradiol (E2), an estrogen, and dydrogesterone (DYD), a progestin, which is used in menopausal hormone therapy, specifically to treat and prevent hot flashes and osteoporosis, in postmenopausal women.Estradiol, also spelled oestradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of the estrous and menstrual female reproductive cycles.Dydrogesterone is a progestin medication which is used for a variety of indications, including threatened or recurrent miscarriage during pregnancy dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, premenstrual syndrome, and as a component of menopausal hormone therapy.Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its products encircle life, from newborns to aging adults, from nutrition and diagnostics through medical care and pharmaceutical therapy

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!